natgillin/translations-raw huggingface dataset:
In table 2 below all adverse reactions, which occurred at an incidence greater than placebo and in more than one patient, are listed by class and frequency: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000), not known (cannot be estimated from the available data).
V spodnji preglednici 2 so po organskih sistemih in pogostnosti navedeni vsi neželeni učinki, ki so se pojavili pri več kot enem bolniku in z incidenco, večjo kot pri placebu (zelo pogosti (≥ 1/10); pogosti (≥ 1/100 do < 1/10); občasni (≥ 1/1.000 do < 1/100); redki (≥ 1/10.000 do < 1/1.000); zelo redki (< 1/10.000); neznana (ni mogoče oceniti iz razpoložljivih podatkov)).
The dose, which has been adjusted for you and your condition, will generally be between 150 mg and 600 mg each day.
Odmerek, prilagojen vam in vaši bolezni, bo praviloma med 150 mg in 600 mg na dan.
The rate of pregabalin absorption is decreased when given with food resulting in a decrease in Cmax by approximately 25 - 30% and a delay in tmax to approximately 2.5 hours.
Hitrost absorpcije pregabalina se zmanjša, če je uporabljen s hrano; Cmax se zmanjša za približno 25-30 % in tmax se podaljša na približno 2,5 ure.
Printing ink
Tiskarsko črnilo
25 mg hard capsules are packed into alu/alu (OPA/alu/PVC/alu) blisters as primary packaging.
25 mg trde kapsule so pakirane v alu/alu (OPA/alu/PVC/alu) pretisnih omotih kot primarni ovojnini.
• A small number of people being treated with anti-epileptics such as pregabalin have had thoughts of harming or killing themselves.
• Pri majhnem številu bolnikov, ki so se zdravili z antiepileptiki, kot je pregabalin, so se pojavile misli na samopoškodovanje ali samomor.
Peripheral and central neuropathic pain, epilepsy or generalised anxiety disorder Take the number of hard capsules as instructed by your doctor.
Periferna in centralna nevropatska bolečina, epilepsija ali generalizirana anksiozna motnja Vzemite toliko trdih kapsul, kot vam je naročil zdravnik.
Patients with rare hereditary problems of galactose intolerance, the total lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Bolniki z redko dedno intoleranco za galaktozo, odsotnostjo encima laktaze ali malabsorpcijo glukoze/galaktozene smejo jemati tega zdravila.
You should not drive, operate complex machinery or engage in other potentially hazardous activities until you know whether this medicine affects your ability to perform these activities.
Ne vozite, ne upravljajte zapletenih strojev in ne sodelujte pri drugih potencialno nevarnih dejavnostih, dokler ne veste, ali to zdravilo poslabša vašo zmožnost za takšne dejavnosti.
The active substance, pregabalin, is a gamma-aminobutyric acid analogue [(S)-3-(aminomethyl)-5methylhexanoic acid].
Učinkovina pregabalin je analog gama-aminomaslene kisline [(S)-3-(aminometil)-5- metilheksanojska kislina].
Infections and infestations Common
Infekcije in okužbe Pogosti
is used to treat a certain form of epilepsy (partial seizures with or without secondary generalisation) in adults.
se uporablja za zdravljenje določene oblike epilepsije (parcialnih napadov s sekundarno generalizacijo ali brez nje) pri odraslih.
The safety and efficacy of pregabalin in children below the age of 12 years and in adolescents (12 - 17 years of age) have not been established.
Varnost in učinkovitost pregabalina pri otrocih, starih do 12 let, in pri mladostnikih (12-17 let) nista bili dokazani.
In accordance with current clinical practice, if pregabalin has to be discontinued it is recommended this should be done gradually over a minimum of 1 week independent of the indication (see sections 4.4 and 4.8).
Če je treba uporabo pregabalina prekiniti, ga je skladno s trenutno klinično prakso, ne glede na indikacijo, priporočljivo zmanjševati postopoma vsaj 1 teden (glejte poglavji 4.4 in 4.8).
is too strong or too weak, talk to your doctor or pharmacist.
premočan ali prešibak, se posvetujte z zdravnikom ali farmacevtom.
Pregabalin binds to an auxiliary subunit (α2-δ protein) of voltage-gated calcium channels in the central nervous system.
Pregabalin se veže na pomožno podenoto (beljakovino α2-δ) napetostno odvisnih kalcijevih kanalčkov v osrednjem živčevju.
The AUC was lower by 30% in paediatric patients below a weight of 30 kg due to an increased body weight adjusted clearance of 43% for these patients in comparison to patients weighing ≥ 30 kg.
Vrednost AUC je bila pri pediatričnih bolnikih, lažjih od 30 kg, za 30 % nižja zaradi povečanega očistka, prilagojenega telesni masi, ki je bil pri teh bolnikih 43 % v primerjavi z bolniki s telesno maso 30 kg ali več.
The degree of dizziness, sleepiness and decreased concentration may be increased if pregabalin is taken together with medicinal products containing:
Omotica, zaspanost ali zmanjšanje sposobnosti koncentracije se lahko stopnjujejo, če pregabalin vzamemo skupaj z zdravili, ki vsebujejo:
is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.
je indicirano kot dodatno zdravljenje pri odraslih s parcialnimi napadi, s sekundarno generalizacijo ali brez nje.
• Pregabalin may cause blurring or loss of vision, or other changes in eyesight, many of which are temporary.
• Uporaba pregabalina lahko povzroči zamegljenost ali izgubo vida ali druge spremembe vida, med katerimi so mnoge začasne.
for you to help treat your epilepsy when your current treatment is not controlling your condition.
kot pomoč za zdravljenje epilepsije, če zdravila, ki jih trenutno uporabljate, bolezni ne obvladujejo.
Lactose intolerance
Intoleranca za laktozo
is indicated for the treatment of peripheral and central neuropathic pain in adults.
je indicirano za zdravljenje periferne in centralne nevropatske bolečine pri odraslih.
In clinical trials up to 12 weeks for both peripheral and central neuropathic pain, a reduction in pain was seen by week 1 and was maintained throughout the treatment period.
V kliničnih preskušanjih v trajanju 12 tednov so tako pri periferni kot centralni nevropatski bolečini že v prvem tednu opazili zmanjšanje bolečine, ki se je ohranilo ves čas zdravljenja.
The N- methylated derivative of pregabalin, the major metabolite of pregabalin found in urine, accounted for 0.9% of the dose.
Na računa N-metiliranega derivata pregabalina, ki je glavni presnovek pregabalina v urinu, je šlo 0,9 % odmerka.
There have also been postmarketing reports of loss of consciousness, confusion and mental impairment.
V obdobju trženja so poročali tudi o izgubi zavesti, zmedenosti in poslabšanju mentalnih sposobnosti.
See section 4.
Preglednica 1.
There are no adequate data from the use of pregabalin in pregnant women.
O uporabi pregabalina pri nosečnicah ni zadostnih podatkov.
Patients are advised not to drive, operate complex machinery or engage in other potentially hazardous activities until it is known whether this medicinal product affects their ability to perform these activities.
Bolnikom je treba svetovati, naj ne vozijo, ne upravljajo zapletenih strojev in ne sodelujejo pri drugih potencialno nevarnih dejavnostih, dokler ni znano, kako to zdravilo vpliva na njihovo zmožnost za takšne dejavnosti.
Tachycardia, atrioventricular block first degree, sinus bradycardia, congestive heart failure
Tahikardija, atrioventrikularni blok prve stopnje, sinusna bradikardija, kongestivno srčno popuščanje
Adjunctive treatment
Dodatno zdravljenje
Urinary incontinence, dysuria
Urinska inkontinenca, dizurija
There are no clinical data on the effects of pregabalin on female fertility.
Ni kliničnih podatkov o vplivu pregabalina na plodnost pri ženskah.
Pregabalin may have minor or moderate influence on the ability to drive and use machines.
Pregabalin ima lahko blag ali zmeren vpliv na sposobnost vožnje in upravljanja strojev.
Anorexia, hypoglycaemia
Anoreksija, hipoglikemija
Stevens-Johnson syndrome, cold sweat Musculoskeletal and connective tissue disorders Common
Stevens-Johnsonov sindrom, hladen znoj Bolezni mišično-skeletnega sistema in vezivnega tkiva Pogosti
TID = Three divided doses.
3-krat/dan = tri deljene odmerke
Pregabalin may cause dizziness and somnolence and therefore may influence the ability to drive or use machines.
Pregabalin lahko povzroči omotico in somnolenco in tako lahko vpliva na sposobnost vožnje in upravljanja strojev.
The 50 mg capsules also contain propylene glycol, strong ammonia solution, potassium hydroxide.
50 mg kapsule vsebujejo tudi propilen glikol, močno raztopino amoniaka, kalijev hidroksid.
once in the morning, once in the afternoon and once in the evening, at about the same time each day.
dvakrat na dan, ga vzemite enkrat zjutraj in enkrat zvečer, in sicer vsak dan ob približno istem času.
The other ingredients are lactose monohydrate, pregelatinized maize starch, talc, titanium dioxide (E171), gelatin, shellac, black iron oxide (E172).
Druge sestavine zdravila so: laktoza monohidrat, pregelirani koruzni škrob, smukec, titanov dioksid (E171), želatina, šelak, črni železov oksid (E172).
• Heart rhythm disturbances, increased heart rate, low blood pressure, high blood pressure, changes in heartbeat, heart failure.
• motnje srčnega ritma, pospešen srčni utrip, nizek krvni tlak, visok krvni tlak, spremembe srčnega utripa, srčno popuščanje
Median 24-hour seizure frequencies at baseline and at the final visit were 4.7 and 3.8 for pregabalin 7 mg/kg/day, 5.4 and 1.4 for pregabalin 14 mg/kg/day, and 2.9 and 2.3 for placebo, respectively.
Mediana 24-urna pogostnost napadov je bila ob izhodišču in končnem obisku 4,7 in 3,8 za pregabalin 7 mg/kg/dan, 5,4 in 1,4 za pregabalin 14 mg/kg/dan, ter 2,9 in 2,3 za placebo.
* Alanine aminotransferase increased (ALT) and aspartate aminotransferase increased (AST).
Zmanjšanje števila levkocitov * zvišanje alanin aminotransferaze (ALT) in aspartat aminotransferaze (AST)
After discontinuation of short-term and long-term treatment with pregabalin withdrawal symptoms have been observed in some patients.
Po prekinitvi kratkotrajnega in dolgotrajnega zdravljenja s pregabalinom so pri nekaterih bolnikih opazili odtegnitvene simptome.
The pregabalin clinical programme involved over 8,900 patients exposed to pregabalin, of whom over 5,600 were in double-blind placebo controlled trials.
Klinični program pregabalina je zajel prek 8.900 bolnikov, izpostavljenih temu zdravilu; 5.600 od teh je bilo vključenih v dvojno slepa, s placebom nadzorovana preskušanja.
in addition to your current treatment.
morate jemati poleg trenutno uporabljanih zdravil.
than you should Call your doctor or go to the nearest hospital emergency unit immediately.
Če ste vzeli večji odmerek zdravila Pregabalin Zentiva k.s., kot bi smeli Pokličite zdravnika ali nemudoma pojdite v ambulanto za nujno pomoč najbližje bolnišnice.
The pregabalin safety profile observed in four paediatric studies in patients with partial seizures with or without secondary generalisation (12-week efficacy and safety study in patients 4 to 16 years of age, n = 295; 14-day efficacy and safety study in patients 1 month to younger than 4 years of age, n = 175; pharmacokinetic and tolerability study, n = 65; and 1 year open label follow on safety study, n = 54) was similar to that observed in the adult studies of patients with epilepsy.
Varnostni profil pregabalina, opažen v štirih študijah pri otrocih s parcialnimi napadi s sekundarno generalizacijo ali brez nje (12-tedenska študija učinkovitosti in varnosti pri bolnikih, starih od 4 do 16 let, n = 295; 14-dnevna študija učinkovitosti in varnosti pri bolnikih, starih od 1 meseca do manj kot 4 leta, n = 175; študija farmakokinetike in prenašanja zdravila, n = 65; in enoletna odprta nadaljevalna študija varnosti, n = 54), je bil podoben tistemu v študijah pri odraslih z epilepsijo.
Pregabalin 14 mg/kg/day significantly reduced the log-transformed partial onset seizure frequency versus placebo (p=0.0223); pregabalin 7 mg/kg/day did not show improvement relative to placebo.
Pregabalin 14 mg/kg/dan je v primerjavi s placebom pomembno zmanjšal logaritemsko pretvorjeno pogostnost parcialnih napadov (p = 0,0223), pregabalin 7 mg/kg/dan pa v primerjavi s placebom ni pokazal izboljšanja.
* Total daily dose (mg/day) should be divided as indicated by dose regimen to provide mg/dose.
2-krat/dan = dva deljena odmerka * Celotni dnevni odmerek (mg/dan) je treba razdeliti, kot navaja odmerna shema, da dobimo mg/odmerek.
Capsules content Lactose monohydrate Pregelatinized maize starch Talc
Vsebina kapsule laktoza monohidrat predgelirani koruzni škrob smukec
Treatment of pregabalin overdose should include general supportive measures and may include haemodialysis if necessary (see section 4.2 table 1).
Zdravljenje prevelikega odmerjanja pregabalina mora obsegati splošne podporne ukrepe in lahko vključuje hemodializo, če je potrebno (glejte poglavje 4.2, preglednico 1).
Appetite increased
Zvečanje apetita
The adverse events observed in a pharmacokinetic and tolerability study that enrolled patients from 3 months to 16 years of age (n = 65) with partial onset seizures were similar to those observed in adults.
Neželeni učinki, opaženi v študiji farmakokinetike in prenašanja, v kateri so sodelovali bolniki s parcialnimi napadi, stari od 3 mesecev do 16 let (n=65), so bili podobni tistim pri odraslih.
• There have been reports of heart failure in some patients when taking pregabalin; these patients were mostly elderly with cardiovascular conditions.
• Pri nekaterih bolnikih, ki so jemali pregabalin, so opisani primeri srčnega popuščanja; večinoma je šlo za starejše bolnike s srčnožilnimi boleznimi.
NAME OF THE MARKETING AUTHORISATION HOLDER Zentiva logo
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM Zentiva logo
contains lactose monohydrate.
vsebuje laktozo monohidrat.
The most common adverse events observed in the 14-day study with pregabalin treatment were somnolence, upper respiratory tract infection, and pyrexia (see sections 4.2, 5.1 and 5.2).
Najpogostejši neželeni učinki, opaženi v 14-dnevni študiji zdravljenja s pregabalinom, so bili somnolenca, okužba zgornjih dihal in pireksija (glejte poglavja 4.2, 5.1 in 5.2).
Results of a 12-week placebo controlled study of 295 paediatric patients aged 4 to 16 years and a 14-day placebo-controlled study of 175 paediatric patients aged 1 month to younger than 4 years of age performed to evaluate the efficacy and safety of pregabalin as adjunctive therapy for the treatment of partial onset seizures and a 1 year open label safety study in 54 paediatric patients from 3 months to 16 years of age with epilepsy indicate that the adverse events of pyrexia and upper respiratory infections were observed more frequently than in adult studies of patients with epilepsy (see sections 4.2, 4.8 and 5.2).
Rezultati 12-tedenske s placebom nadzorovane študije pri 295 pediatričnih bolnikih, starih od 4 do 16 let, in 14-dnevne s placebom nadzorovane študije pri 175 pediatričnih bolnikih, starih od 1 meseca do manj kot 4 leta, ki so jo izvedli za ovrednotenje učinkovitosti in varnosti pregabalina kot dodatne terapije za zdravljenje parcialnih napadov, in enoletne odprte študije varnosti pri 54 pediatričnih bolnikih z epilepsijo, starih od 3 mesecev do 16 let, kažejo, da so opazili neželene učinke - pireksijo in okužbe zgornjih dihalpogosteje kot v študijah pri odraslih z epilepsijo (glejte poglavja 4.2, 4.8 in 5.2).
Pregabalin has been studied in 6 controlled trials of 4 - 6 week duration, an elderly study of 8 week duration and a long-term relapse prevention study with a double blind relapse prevention phase of 6 months duration.
Pregabalin so raziskovali v 6 nadzorovanih preskušanjih, ki so trajala od 4 do 6 tednov, v študiji starejših bolnikov, ki je trajala 8 tednov, ter v dolgoročni študiji preprečevanja recidiva s 6-mesečno dvojno slepo fazo preprečevanja recidiva.
As pregabalin clearance is directly proportional to creatinine clearance (see section 5.2), dose reduction in patients with compromised renal function must be individualised according to creatinine clearance (CLcr), as indicated in table 1 determined using the following formula.
Očistek pregabalina je neposredno sorazmeren očistku kreatinina (glejte poglavje 5.2), zato je treba pri bolnikih z okrnjenim delovanjem ledvic odmerek individualno prilagoditi glede na očistek kreatinina (OČkr), kot prikazuje preglednica 1, po naslednji formuli:
Investigations Common
Preiskave Pogosti
Based on individual patient response and tolerability, the dose may be increased to 300 mg per day after an interval of 3 to 7 days, and if needed, to a maximum dose of 600 mg per day after an additional 7-day interval.
Glede na bolnikov odziv in prenašanje je mogoče čez 1 do 7 dni odmerek zvečati na 300 mg na dan in - če je potrebno - čez nadaljnjih 7 dni na največji odmerek 600 mg na dan.
Capsule body
Telo kapsule
belongs to a group of medicines used to treat epilepsy, neuropathic pain and generalised anxiety disorder (GAD) in adults.
sodi med zdravila, ki se uporabljajo za zdravljenje epilepsije, nevropatske bolečine in generalizirane anksiozne motnje pri odraslih.
Dizziness, somnolence, headache
Omotica, somnolenca, glavobol
• When pregabalin is taken with other medicines that may cause constipation (such as some types of pain medicines) it is possible that gastrointestinal problems may occur (e.g. constipation, blocked or paralysed bowel).
• Ob sočasni uporabi pregabalina z ostalimi zdravili, ki lahko povzročijo zaprtost (kot so nekatera zdravila proti bolečinam), obstaja možnost pojava prebavnih težav (npr. zaprtje, zaprto ali paralizirano črevo).
with food, drink and alcohol Pregabalin Zentiva k.s.
skupaj s hrano, pijačo in alkoholom Trde kapsule Pregabalin Zentiva k.s.
• Some patients taking pregabalin have reported symptoms suggesting an allergic reaction.
• Nekateri bolniki, ki so jemali pregabalin, so imeli simptome alergijske reakcije.
Pregabalin pharmacokinetics were evaluated in paediatric patients with epilepsy (age groups: 1 to 23 months, 2 to 6 years, 7 to 11 years and 12 to 16 years) at dose levels of 2.5, 5, 10 and 15 mg/kg/day in a pharmacokinetic and tolerability study.
Farmakokinetiko pregabalina so ocenili v študiji farmakokinetike in prenašanja pri pediatričnih bolnikih z epilepsijo (starostne skupine: od 1 do 23 mesecev, od 2 do 6 let, od 7 do 11 let in od 12 do 16 let) z odmerki 2,5; 5, 10 in 15 mg/kg/dan.
Hepatic failure, hepatitis
Odpoved jeter, hepatitis
When taken with certain other medicines, pregabalin may potentiate the side effects seen with these medicines, including respiratory failure and coma.
Kadar ga vzamemo z določenimi drugimi zdravili, lahko pregabalin stopnjuje neželene učinke teh zdravil, kar lahko vodi do zmanjšanega delovanja dihal in kome.
Convulsions, parosmia, hypokinesia, dysgraphia
Konvulzije, parozmija, hipokinezija, disgrafija
Rash papular, urticaria, hyperhidrosis, pruritus
Papulozni izpuščaj, urtikarija, hiperhidroza, pruritus
If you have the impression that the effect of Pregabalin Zentiva k.s.
Če imate občutek, da je učinek zdravila Pregabalin Zentiva k.s.
LIST OF EXCIPIENTS Contains lactose monohydrate.
SEZNAM POMOŽNIH SNOVI Vsebuje laktozo monohidrat.
is indicated for the treatment of generalised anxiety disorder (GAD) in adults.
je indicirano za zdravljenje generalizirane anksiozne motnje (GADGeneralised Anxiety Disorder) pri odraslih.
• Pregabalin has been associated with dizziness and somnolence, which could increase the occurrence of accidental injury (fall) in elderly patients.
• Zdravljenje s pregabalinom lahko spremljata omotica in zaspanost, ki lahko pri starejših bolnikih zvečata pogostnost nezgodnih poškodb (padcev).
In the clinical studies where ophthalmologic testing was conducted, the incidence of visual acuity reduction and visual field changes was greater in pregabalin-treated patients than in placebo-treated patients; the incidence of fundoscopic changes was greater in placebo-treated patients (see section
V kliničnih študijah, ki so vključevale oftalmološke preglede, je bila incidenca zmanjšane ostrine vida in sprememb vidnega polja večja med bolniki, ki so dobivali pregabalin, kot med tistimi, ki so dobivali placebo, incidenca fundoskopskih sprememb pa je bila večja pri bolnikih, ki so dobivali placebo (glejte poglavje 5.1).
In addition to the daily dose, a supplementary dose should be given immediately following every 4 hour haemodialysis treatment (see table 1).
Poleg dnevnega odmerka morajo bolniki takoj po vsaki 4-urni hemodializi dobiti dodaten odmerek (glejte preglednico
The most common adverse events observed in the 12-week study with pregabalin treatment were somnolence, pyrexia, upper respiratory tract infection, increased appetite, weight increased, and nasopharyngitis.
Najpogostejši neželeni učinki, opaženi v 12-tedenski študiji zdravljenja s pregabalinom, so bili somnolenca, pireksija, okužba zgornjih dihal, zvečanje apetita, zvečanje telesne mase in nazofaringitis.
In the 14-day placebo-controlled study, paediatric patients (1 month to younger than 4 years of age) were assigned to pregabalin 7 mg/kg/day, pregabalin 14 mg/kg/day, or placebo.
V 14-dnevni s placebom nadzorovani študiji so pediatrične bolnike (stare od 1 meseca do manj kot 4 leta) razvrstili v skupine, ki so prejemale pregabalin 7 mg/kg/dan, pregabalin 14 mg/kg/dan ali placebo.
is used to treat generalised anxiety disorder (GAD).
se uporablja za zdravljenje generalizirane anksiozne motnje (GADGeneralised Anxiety Disorder).
Funduscopic changes were observed in 1.7% of pregabalintreated and 2.1% of placebo-treated patients.
Fundoskopske spremembe so ugotovili pri 1,7 % bolnikov, ki so dobivali pregabalin, in pri 2,1 % bolnikov, ki so dobivali placebo.
Hyperacusis
Hiperakuza
• Changes in blood and liver test results (blood creatinine phosphokinase increased, alanine aminotransferase increased, aspartate aminotransferase increased, platelet count decreased,
• spremembe izvidov preiskav krvi in delovanja jeter (povečanje vrednosti encimov kreatin fosfokinaze v krvi, povečanje vrednosti alanin aminotransferaze, povečanje vrednosti aspartat aminotransferaze, zmanjšanje števila krvnih ploščic (trombocitov), zmanjšanje števil nevtrofilcev v krvi, povečanje vrednosti kreatinina v krvi, zmanjšanje vrednosti kalija v krvi)
Blood and lymphatic system disorders Uncommon
Bolezni krvi in limfatičnega sistema Občasni
is and what it is used for What you need to know before you take Pregabalin Zentiva k.s.
in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Pregabalin Zentiva k.s.
Euphoric mood, confusion, irritability, disorientation, insomnia, libido decreased
Evforično razpoloženje, zmedenost, razdražljivost, dezorientiranost, nespečnost, zmanjšanje libida
QUALITATIVE AND QUANTITATIVE COMPOSITION Pregabalin Zentiva k.s.
KAKOVOSTNA IN KOLIČINSKA SESTAVA Pregabalin Zentiva k.s.
In the treatment of central neuropathic pain due to spinal cord injury the incidence of adverse reactions in general, CNS adverse reactions and especially somnolence was increased (see section 4.4).
Pri zdravljenju centralne nevropatske bolečine kot posledice poškodbe hrbtenjače, je bila povečana incidenca neželenih učinkov na splošno, neželenih učinkov, povezanih z osrednjim živčnim sistemom, in še posebno somnolence (glejte poglavje 4.4).
• Muscle twitching, joint swelling, muscle stiffness, pain including muscle pain, neck pain.
• trzanje mišic, otekanje sklepov, mišična togost, bolečina, vključno z bolečino v mišicah,
• There have been reports of convulsions when taking pregabalin or shortly after stopping pregabalin.
• Med jemanjem pregabalina ali kmalu po prenehanju jemanja so poročali o primerih krčev.
U Kabelovny 130 Dolni Měcholupy 102 37 Prague 10 Czech Republic
U Kabelovny 130 Dolni Měcholupy 102 37 Prague 10 Češka republika
Because renal elimination is the major elimination pathway, dose reduction in patients with renal impairment and dose supplementation following haemodialysis is necessary (see section 4.2 table 1).
Ker je izločanje skozi ledvice glavna pot izločanja, je treba pri bolnikih z okvaro ledvic odmerek zmanjšati, po hemodializi pa ustrezen odmerek dodati (glejte poglavje 4.2, preglednico 1).
What you need to know before you take Pregabalin Zentiva k.s.
Kaj morate vedeti, preden boste vzeli zdravilo Pregabalin Zentiva k.s.